Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: Implications for influenza epidemic control

Vaccine

Volumn 18, Issue 18, 2000, Pages 1902-1909

  Longini Jr , Ira M ^a   Halloran, M Elizabeth ^a   Nizam, Azhar ^a   Wolff, Mark ^b   Mendelman, Paul M ^c   Fast, Patricia E ^c   Belshe, Robert B ^d  

^a EMORY UNIVERSITY   (United States)

^b EMMES CORPORATION   (United States)

^c MEDIMMUNE   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Child; Influenza vaccine; Multicenter trials

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIDEMIC; HUMAN; INFLUENZA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PLACEBO EFFECT; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 0343502994     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00419-3     Document Type: Article

References (27)

1. Glezen P., Paredes A., Taber L.H. Influenza in children. JAMA. 243:1980;1345-1349.
2. Piedra P.A., Glezen P. Influenza in children: Epidemiology, immunity, and vaccines. Semin. Pediatr. Infect. Dis. 2:1991;140-146.
3. Glezen P., Couch R.B. Influenza viruses. Evans A.S. Virus infections in humans: epidemiology and control. 3rd ed. 1989;429-449 Plenum, New York.
4. Monto A.S., Koopman J.S., Longini I.M. The Tecumseh study of illness. XII. Influenza infection and disease, 1976-1981. Am. J. Epidemiol. 121:1985;811-822.
5. Monto A.S., Davenport J.A., Napier J.A., Francis T.F. Effect of vaccination of a school-age population upon the course of an A2/Hong Kong influenza epidemic. Bull. Who. 41:1969;537-542.
6. Longini I.M., Ackerman E., Elveback L.R. An optimization model for influenza A epidemics. Math. Biosci. 38:1978;141-157.
7. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr., 1999, in print.
8. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med. 20:1998;1405-1412.
9. Edwards K.M., Dupont W.D., Westrich M.K., et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 169:1994;68-76.
10. Nichol K.L., Mendelman P.M., Mallon K.P., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults. JAMA. 282:1999;137-144.
11. Halloran M.E., Haber M.J., Longini I.M., Struchiner C.J. Direct and indirect effects in vaccine field efficacy and effectiveness. Am. J. Epidemiol. 133:1991;323-331.
12. Halloran M.E., Struchiner C.J., Longini I.M. Study designs for different efficacy and effectiveness aspects of vaccination. Am. J. Epidemiol. 146:1997;789-803.
13. Donner A. Some aspects of the design and analysis of cluster randomized trials. Appl. Stat. 47:1998;95-113.
14. Gould A.L. Multi-center trial analysis revisited. Stat. Med. 17:1998;1779-1787.
15. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. 1999, in preparation.
16. Longini I.M., Halloran M.E., Haber M.J., Chen R.T. Measuring vaccine efficacy from epidemics of acute infectious agents. Stat. Med. 12:1993;249-263.
17. Halloran M.E., Longini I.M., Struchiner C.J. Estimation and interpretation of vaccine efficacy using frailty mixing models. Am. J. Epidemiol. 144:1996;83-97.
18. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R.D. SAS(R) System for mixed models. 1996;SAS Institute, Inc, Cary, NC.
19. Lin A. An issue of statistical analysis in controlled multi-centre studies: How shall we weight the centres? Stat. Med. 18:1999;365-373.
20. Gilbert P.B., Self S.G., Ashby M.A. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics. 54:1998;799-814.
21. Ackerman E., Longini I.M., Seaholm S.K., Hedin A.S. Stimulation of mechanisms of viral interference in influenza. Int. J. Epidemiol. 19:1990;444-454.
22. Longini I.M., Koopman J.S., Haber M., Cotsonis G.A. Statistical inference for infectious diseases: Risk-specified household and community transmission parameters. Am. J. Epidemiol. 128:1988;845-859.
23. Clover R.D., Crawfod S., Glezen W.P., et al. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccinesto A/Chile/83-like virus. J. Infect. Dis. 163:1991;300-304.
24. Longini IM. Optimal control of influenza A epidemics. Ph.D. thesis, University of Minnesota, 1977.
25. Longini I.M., Sagatelian K., Rida W.N., Halloran M.E. Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. Stat. Med. 17:1998;1121-1136.
26. Elveback L.R., Fox J.P., Ackerman E., et al. An influenza simulation model for immunization studies. Am. J. Epidemiol. 103:1976;152-165.
27. Halloran ME, Longini IM, Cowart DM. Indirect effects of influenza vaccination: Implications for design of community trials. In preparation.